In a pivotal shift for the obesity treatment market, Eli Lilly and Company (NYSE: LLY) has secured formulary coverage across all three of America’s largest pharmacy benefit managers — CVS Caremark, Express Scripts, and OptumRx — for its complete obesity portfolio: Foundayo™ (orforglipron) and Zepbound® (tirzepatide).
CVS Caremark’s commercial coverage for Foundayo activated June 1, 2026, with Zepbound reinstated as a preferred option effective October 1 — reversing a year-long exclusion in favour of rival Novo Nordisk’s Wegovy. The realignment puts both GLP-1 giants on equal formulary footing across plans covering an estimated 25–30 million Americans.
Commercially insured patients may now access either drug foras little as $25 per month, with Medicare Part D eligibility expanding to $50 per month from July 1.
Foundayo, FDA-approved in April 2026 as the first food-and-water-restriction-free oral GLP-1 pill, anchors Lilly’s growing dominance in the blockbuster weight-loss segment.
Written By: Sayan Das
Graphics by : Pramit Hazra
